What Is CJC-1295?
Research Use Only: CJC-1295 is intended strictly for in-vitro laboratory research purposes only. Not for human consumption, medical treatment, or veterinary use. Read our full disclaimer.
What Is CJC-1295?
CJC-1295 (without DAC) is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of endogenous GHRH with stabilising substitutions. In laboratory research, CJC-1295 No DAC is studied for its role in growth hormone pulse amplification, pituitary somatotroph signalling and GH/IGF-1 axis research in experimental models. It is frequently used in combination with Ipamorelin to study synergistic GH secretagogue effects.
CJC-1295 No DAC vs CJC-1295 with DAC
CJC-1295 exists in two research forms. The No DAC (without Drug Affinity Complex) version, also known as Modified GRF(1-29), produces discrete GH pulses that more closely mimic endogenous pulsatile GH secretion patterns. The DAC version incorporates a lysine-maleimide linker that binds to albumin, extending half-life significantly. Solatide Biosciences supplies the No DAC form, which is preferred in laboratory models studying physiological GH pulse dynamics.
Mechanism of Action
CJC-1295 No DAC binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, stimulating GH synthesis and secretion. Its stabilising amino acid substitutions, including Ala2 to D-Ala, Gln8 to Ala, Asn11 to Ala and Tyr13 to Leu, confer resistance to DPP-IV and other proteases, extending activity relative to native GHRH(1-29) in experimental settings.
GH/IGF-1 Axis Activation
In laboratory models, CJC-1295-stimulated GH release drives hepatic IGF-1 production, enabling researchers to study the complete GH/IGF-1 axis including downstream anabolic signalling, lipolytic effects and tissue-specific IGF-1 receptor activation.
Research Applications
Growth Hormone Secretagogue Research
CJC-1295 No DAC is used in laboratory models to investigate GHRH receptor signalling, GH pulse dynamics and somatotroph cell biology. It is a standard tool compound for studying the hypothalamic-pituitary GH axis in vitro.
CJC-1295 + Ipamorelin Combination Research
CJC-1295 No DAC is frequently combined with Ipamorelin in laboratory research to study synergistic GH secretagogue effects. CJC-1295 activates GHRH receptors while Ipamorelin activates ghrelin/GHS receptors (GHSR), providing complementary and additive stimulation of GH release. This combination is used to investigate receptor crosstalk and cooperative GH secretion mechanisms in experimental models. Read the Ipamorelin overview
Metabolic & Body Composition Research
Laboratory investigations employ CJC-1295 to study GH-mediated effects on lipid metabolism, glucose homeostasis and protein synthesis signalling in cellular models. It is relevant to research into metabolic regulation downstream of GH axis activation.
Structural Characteristics
CJC-1295 No DAC is a 29-amino-acid peptide corresponding to GHRH(1-29) with four stabilising substitutions (MW approximately 3368 Da). It lacks the maleimide-lysine DAC modification present in the longer-acting CJC-1295 with DAC variant. The No DAC form is water-soluble and suitable for reconstitution in standard aqueous laboratory buffers.
Storage & Handling
Store lyophilised CJC-1295 at -20°C or -80°C, protected from light and moisture. Reconstitute with bacteriostatic water prior to use. Use the Concentration Calculator to determine the correct volume for your target concentration. Follow institutional laboratory protocols for handling and disposal.
Quality & Documentation
Solatide Biosciences CJC-1295 No DAC + Ipamorelin is independently third-party tested to >=99% purity, verified by HPLC and mass spectrometry. A Certificate of Analysis is available on the product page.
Related Compounds
Research Use Only: All compounds are manufactured for in-vitro laboratory research and are not intended for human consumption, medical use, or veterinary applications. Full disclaimer.